Skip to content
Peptigraph home

Mounjaro vs Zepbound: What the Research Shows

Mounjaro and Zepbound side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Brand of Tirzepatide (GLP-1 / GIP dual agonist)FDA approved (Mounjaro, Zepbound)MounjaroEli Lilly's tirzepatide brand for diabetes; the label covers glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes.[5]GLP-1 & metabolic
Brand of Tirzepatide (GLP-1 / GIP dual agonist)FDA approved (Mounjaro, Zepbound)ZepboundEli Lilly's tirzepatide brand for weight management, labeled to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight plus a comorbidity.[10]GLP-1 & metabolic
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Mounjaro if…

  • you need a type 2 diabetes label: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes[5]
  • you want a label that includes cardiovascular risk reduction: Mounjaro is indicated to reduce major cardiovascular events in adults with type 2 diabetes at high risk[5]

Consider Zepbound if…

  • you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[10]
  • you want the label that also covers obstructive sleep apnea: Zepbound is indicated for moderate to severe obstructive sleep apnea in adults with obesity[10]

What they have in common

  • Mounjaro's FDA record lists tirzepatide (Eli Lilly)[11]
  • Zepbound's FDA record also lists tirzepatide (Eli Lilly)[11]
Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing all 11 fields. Highlighted rows differ.

FieldMounjaroZepbound
ClassBrand of Tirzepatide (GLP-1 / GIP dual agonist)Brand of Tirzepatide (GLP-1 / GIP dual agonist)
Also calledBrand name of TirzepatideBrand name of Tirzepatide
CategoryGLP-1 & metabolicGLP-1 & metabolic
FDA statusFDA approved (Mounjaro, Zepbound)FDA approved (Mounjaro, Zepbound)
PCAC vote, Jul 2026Not on the Jul 2026 agendaNot on the Jul 2026 agenda
WADANot on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Half-lifeapproximately 5 dayssubcutaneous · FDA label (Mounjaro)approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Evidence strengthHuman RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163
Human studies we summarised24 human (22 randomized or controlled) of 30 summarised24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Named in FDA warning letters, 2026Yes (24 Aug 2026; 31 Mar 2026)Yes (24 Aug 2026; 31 Mar 2026)

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  7. 7Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  8. 8Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  9. 9PubMed search: (Mounjaro[tiab]) AND (Zepbound[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  11. 11Drugs@FDA (openFDA) search: active ingredient "tirzepatide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.